214 results about "Trisaccharide" patented technology

Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.

The invention pertains to a liquid complete nutritional composition suitable for feeding cachectic patients, having an energy density of at least 1.45 kcal/ml. The composition comprises a protein fraction in an amount of 7.8-12 g per 100 ml, a carbohydrate fraction, and a lipid fraction. At least 70 wt. % of the protein fraction can be obtained by demineralising milk, e.g. by ultrafiltration. The carbohydrate fraction (17-27 g per 100 ml) can comprise 0-35 wt. % of sucrose, 15-45 wt. % of other non-reducing mono-, di- and/or tri-saccharides, especially trehalose, 5-50 wt. % of other mono-and disaccharides and 5-40 wt. % of tri- and higher saccharides. The product is suitably packaged in small volumes (10-150 ml).

The invention discloses an alginate lyase (Alg509) derived from marine bacteria and a gene thereof, and also disclosed a method for recombinant expression and preparation of the alginate lyase. According to the method, the alg509 gene is cloned into an E. coli expression vector, and the vector is transformed into an E. coli host strain to obtain a recombinant engineering strain which can heterologously express the enzyme. The alginate lyase Alg509 disclosed in the invention has high enzyme activity, the specific enzyme activity can reach up to 48000 U/mg and above, the optimum reaction pH is 10, the optimum reaction temperature is 55 DEG C, and the enzyme activity has no dependence on various metal ions. The enzyme is active to sodium alginate, poly-guluronic acid (polyG) and ploymannuronic acid (polyM), and can completely degrade sodium alginate to produce alginate oligomers such as alginate disaccharide, alginate trisaccharide, alginate tetrasccharide, etc. The enzyme exhibits strongbasophilia, has certain tolerance to high pH, has certain potential of industrial applications, and can be widely applied in the fields of agriculture, food, feed additive, medicine and the like.

The invention discloses genetically engineered bacteria capable of increasing the yield of lactoyl-N-trisaccharide II and a production method, and belongs to the field of microbial genetic engineering. According to the invention, the expression of glmM, glmU, glmS and lgtA in a lactoyl-N-trisaccharide II synthetic pathway is regulated and controlled in a combined manner, so the carbon flux of a metabolic pathway is accurately regulated and controlled, and the metabolic pressure is relieved; the expression of wecB, nagB and lacZ in an escherichia coli host, namely the lactoyl-N-trisaccharide IIsynthetic pathway is knocked out, so the yield of the lactoyl-N-trisaccharide II is further increased; in a flask shaking experiment, the capacity of escherichia coli for producing the lactoyl-N-trisaccharide II is increased to 4.82 g/L from 0.53 g/L; in a fermentation tank with a volume of 3 L, the yield of the lactoyl-N-trisaccharide II reaches 46.2 g/L; and thus, thegenetically engineered bacteria have industrial application prospect.

A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of a drug dissolved or dispersed in an aqueous medium. The aqueous medium consists essentially of water, about 3% to about 10% w/v polyvinylpyrrolidone, about 60% to about 75% w/v of C₃-C₆ polyol that includes more than 55% w/v of a non-reducing disaccharide, trisaccharide or tetrasaccharide such as sucrose, optionally about 0.01% to about 0.5% w/v of a glycyrrhetic acid, glycyrrhizinate derivative or salt thereof, and one or more flavorants, and preferably includes one or more preservatives. The liquid composition is room temperature stable, and may have a pleasant taste.

The emulsion composition of the present invention contains

• • (A) 0.001 to 10 wt. % of an organic compound having two or more hydroxyl groups, an inorganic value of 220 to 450, and an organic value of 300 to 1,000;
  • (B) 0.001 to 10 wt. % of an organic compound having one hydroxyl group, an inorganic value of 100 to 200, and an organic value of 280 to 700;
  • (C) 0.001 to 10 wt. % of a compound represented by formula (2):

wherein R¹ is a C4 to C30 hydrocarbon group; Z is a methylene group, a methine group, or an oxygen atom; X¹, X², X³ is a hydrogen atom, a hydroxyl group, or an acetoxy group; X⁴ is a hydrogen atom, an acetyl group, or a glyceryl group; each of R² and R³ a hydrogen atom, a hydroxyl group, a hydroxymethyl group, or an acetoxymethyl group; R⁴ is a C5 to C60 hydrocarbon group; and R⁵ is a hydrogen atom or a hydrocarbon group containing 1 to 30 carbon atoms in total;

(D) 0.00012 to 10 wt. % of at least one compound selected from the group consisting of a nonionic surfactant having a polyoxyethylene group and an HLB of 10 or higher, an ionic surfactant, and a sphingosine salt;

(E) 0.003 to 15 wt. % of at least one compound selected from the group consisting of a sugar alcohol selected from the group consisting of erythritol, threitol, xylitol, and mannitol, a disaccharide, and a trisaccharide; and

(F) water.

The present invention relates to a method for preparation of the trisaccharide 6′-0-sialyllactose (formula (I)) or salts thereof as well as intermediates in the synthesis and for the use of 6′-0-sialyllactose salts in pharmaceutical or nutritional compositions.

A reduced sugar presweetened ready to eat breakfast cereal is prepared by coating dried cereal base pieces or food pieces with a reduced-sugar composition comprising maltotriose, maltotetrose in full or partial substitution for sucrose, and a high potency sweetener. The reduced-sugar coating can have a sucrose content of less than 70%, yet provides taste, texture, appearance, and bowl life that mimics presweetened R-T-E cereals having a coating with more sucrose.

A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of prednisolone sodium phosphate (PSP) dissolved or dispersed in an aqueous medium that is free of ethanol. The aqueous medium consists essentially of water, about 3 to about 10 weight percent polyvinylpyrrolidone, about 60 to about 75 weight percent of a C₃-C₆ polyol that includes more than 55 weight percent non-reducing disaccharide or trisaccharide such as sucrose, about 0.01 to about 0.5 weight percent ammonium glycyrrhizinate and one or more flavorants, and preferably includes one or more preservatives. The liquid composition is transparent and has a pleasant taste.

The present invention provides preparations of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids. The present invention also provides novel monosaccharides, disaccharides, trisaccharides and pentasaccharides for use in the preparation of heparinoids.

The invention relates to a method for producing low-sugar low-fat lotus paste through enzymolysis processing. The method comprises the following specific steps of: raw material soaking, pectinase addition for peeling, thorough cooking, pulp grinding, enzyme addition for liquidation, burdening, grinding by a colloid grinder, frying, stuffing, packaging and sterilization, and finished product obtaining. The method is characterized in that the peeling by using pectinase is used for replacing conventional subtraction peeling, and after cooked lotus seeds are ground into pulp, one half of pulp is liquefied by using middle-temperature starch, so that the starch in lotus seeds is liquefied into oligosaccharide such as dextrin, trisaccharide and disaccharide; and the other half of ground lotus seeds, sugar, vegetable oil and other ingredients are added into the liquefied lotus seed pulp, and the low-sugar low-fat lotus paste is obtained by using the colloid grinder for grinding the mixture and frying stuffing. Compared with conventional produced lotus paste, the low-sugar low-fat lotus paste produced by the method has the advantages that the addition amounts of white sugar and oil are reduced by about 50%.

The invention discloses chitosanase having an amino acid sequence as shown in SEQ ID NO.1. A gene encoding the chitosanase has a nucleotide sequence as shown in SEQ ID NO.2. The chitosanase is derivedfrom the GH5 family of glucoside hydrolase, can degrade chitosan to generate GlcN-(GlcN)4 and can be used for preparing an enzymatic COS mixture of a new component. The chitosanase has excellent biocatalytic activity, can hydrolyze chitosan to generate glucosamine, chitobiose, chitotriose and chitotetraose hydrochloride, and is relatively high in product purity; and when the pH is 10 and temperature is 50 DEG C, the chitosanase has relatively enzymatic activity of 898.6U/mg which is higher than those of most other known chitosanase, can effectively degrade chitosan, has mild reaction condition, easy control, high efficiency, environmental friendliness. The chitosanase has an industrial application value for producing novel chitosanase mixture.

The invention discloses a method for preparing kestose and nystose through yacon. Method of water extraction by alcohol sedimentation is adopted and supernate thereof is taken, concentrated, frozen and dried to obtain faint yellow yacon oligosaccharide. The yacon oligosaccharide is analyzed through high pressure liquid chromatography with a chromatography condition as follows: a chromatographic column is APS-2HYPERSIL, a column temperature is 30 DEG C, a moving phase is acetonitrile-water (75 to 25, V/V), a flow velocity is 0.8ml/min, a sample size is 20 Mul and a differential detector is arranged. The yacon oligosaccharide comprises fructose, glucose, saccharose, kestose, nystose and 1F-Fructofuranosyl nystose with contents respectively as 38,30 percent, 16.44 percent, 14.58 percent, 12.29 percent, 12.17 percent and 6.2 percent. Silicagel column chromatography is implemented on a prepared oligosaccharide sample; glacial acetic acid, chloroform, absolute ethyl alcohol and water with a proportion of 3 to 11 to 11 to 1 are used as an eluant for elution; the eluant is collected in sequence and then is concentrated, frozen and dried to obtain the kestose and nystose. The purity of the kestose and nystose prepared through high pressure liquid chromatography can be more than 90 percent.

A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I:

or a pharmaceutically acceptable salt thereof, wherein R₁ is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.

The invention relates to incision difunctional alginate lyase Aly2 generating various monosaccharide products, an encoding gene of the Aly2 and an application of the Aly2. The amino acid sequence of the Aly2 is as shown in SEQ ID NO. 2, and the nucleotide sequence of the encoded Aly2 is as shown in SEQ ID NO. 1. The specific activity of prepared gene engineering recombinant protein rAly2 for alginate, polyguluronic acid and polymannuronic acid is 2025U/mg, 3672U/mg and 1324U/mg, so that the gene engineering recombinant protein rAly2 is a difunctional enzyme. The enzyme is an incision enzyme, and final main products are unsaturated disaccharide and unsaturated trisaccharide when an alginate polysaccharide substrate is thoroughly degraded. When different oligosaccharide substrates are degraded, various monosaccharide products such as saturated M and G or unsaturated delta can be generated. Besides, the rAly2 is stable in biochemical property, is a potential tool enzyme, can be applied tothe field of medicines, food and the like and has a wide application prospect.

In a composition comprising a therapeutic agent and a compound which is a trisaccharide or higher polysaccharide, that compound has the formula X[—Y-Z]_n wherein X and Z are each saccharide molecules in which none, some or all OH groups are derivatised; Y is an ester linkage to an exocyclic C atom in X; and n in an integer.

The invention discloses an alginate lyase encoding gene, and belongs to the technical field of biology. Alginate lyase is high in degrading activity and stable in property, enzyme activity reaches 65U/mg, 98% or more of initial enzyme activity is still kept after the alginate lyase is stored for 18 months at the temperature of 4 DEG C, the alginate lyase has high product specificity, and brown algae oligosaccharide trisaccharide can be specifically produced. The alginate lyase has important industrial application values and scientific research values.

The invention discloses an amino acid sequence and a nucleotide sequence of a heat-resisting alkali-resisting and salt stable inulase exonuclease, and construction and application of an inulase exonuclease recombinant expression vector. Results of enzymatic property research show that the optimum reaction conditions of the inulase exonuclease are as below: pH 7.0, 50 DEG C and 10% NaCl. The enzyme can catalyze the hydrolysis of inulase, levan, sucrose, raffinose, kestose, nystose and Kestopentaose. In a catalysis process using inulase as a substrate, only generation of fructose is detected rather than oligosaccharide or other carbohydrates. The inulase exonuclease provided by the invention can be applied to the field of food industry and biological energy source as a novel biocatalyst for fructose production.

The invention discloses an aspergillus niger which is classified and named aspergillus niger M1 with the preservation number being CCTCC NO: M2014421. The preservation date is September 23nd, 2014, and the preservation department is China Center for Type Culture Collection. Alpha-glucosidase produced by the aspergillus niger M1 strain is endoenzyme, and the aspergillus niger M1 strain can produce isomaltose hypgather containing more than 65% of active trisaccharide (IG+P+IG3) under the condition of high temperature. The required reaction time of preparing IMO-500 type isomaltose hypgather containing 35% of active trisaccharide is only half of the reaction time of preparing the isomaltose hypgather containing more than 65% of active trisaccharide. The alpha-glucosidase produced by the strain has advantages of excellent temperature characteristic, short glucoside conversion time, high content of the active trisaccharide in the product and the like.